GlassScriptPhysician profile
Mary Angelopoulos
NPI 1417069022
$24,316.96
in general payments reported to CMS, 2019-2025
56 companies · $2,034 in 2025
The $2,034 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,684 · 2020: $2,743 · 2021: $5,692 · 2022: $3,205 · 2023: $2,373 · 2024: $2,587 · 2025: $2,034.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,993.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,993.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,898.80 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $2,035.23 | 2019-2025 | |
| Livanova USA, INC. | $1,813.31 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Biogen, INC. | $1,434.96 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Ucb, INC. | $1,429.42 | 2019-2025 | Briviact |
| Abbvie INC. | $1,341.71 | 2019-2025 | Ubrelvy, Qulipta |
| Lilly USA, LLC | $1,335.56 | 2019-2025 | Emgality, Amyvid, Kisunla |
| Neurocrine Biosciences, INC. | $1,300.63 | 2019-2025 | Ingrezza, Ongentys |
| Amgen INC. | $1,018.99 | 2019-2025 | Uplizna, Aimovig |
| Teva Pharmaceuticals USA, INC. | $847.96 | 2019-2025 | Austedo Xr |
| Celgene Corporation | $845.56 | 2021-2025 | Zeposia |
| Pfizer INC. | $824.25 | 2019-2025 | |
| Emd Serono, INC. | $751.80 | 2019-2023 | Mavenclad |
| Banner Life Sciences, LLC | $570.61 | 2021-2024 | |
| Genentech USA, INC. | $563.56 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Angelopoulos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.